Mangia A, Cotugno R, Cocomazzi G, Squillante MM, Piazzolla V. Hepatitis C virus micro-elimination: Where do we stand? World J Gastroenterol 2021; 27(16): 1728-1737 [PMID: 33967553 DOI: 10.3748/wjg.v27.i16.1728]
Corresponding Author of This Article
Alessandra Mangia, MD, Chief Doctor, Liver Unit, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, San Giovanni Rotondo 71013, Fg, Italy. a.mangia@tin.it
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 28, 2021; 27(16): 1728-1737 Published online Apr 28, 2021. doi: 10.3748/wjg.v27.i16.1728
Hepatitis C virus micro-elimination: Where do we stand?
Alessandra Mangia, Rosa Cotugno, Giovanna Cocomazzi, Maria Maddalena Squillante, Valeria Piazzolla
Alessandra Mangia, Rosa Cotugno, Giovanna Cocomazzi, Maria Maddalena Squillante, Valeria Piazzolla, Liver Unit, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo 71013, Fg, Italy
Author contributions: Mangia A designed the review, supervised the drafting of the manuscript, and finalized the version for publication; Cotugno R and Squillante MM searched the literature and collected the references; Piazzolla V and Cocomazzi G wrote the first draft of the manuscript.
Conflict-of-interest statement: Mangia A has served in an advisory role and received research grants from Gilead Sciences, MSD, Intercept, and Spring Bank; all other authors declare having no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Alessandra Mangia, MD, Chief Doctor, Liver Unit, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, Viale Cappuccini 1, San Giovanni Rotondo 71013, Fg, Italy. a.mangia@tin.it
Received: January 14, 2021 Peer-review started: January 14, 2021 First decision: February 10, 2021 Revised: February 28, 2021 Accepted: April 5, 2021 Article in press: April 5, 2021 Published online: April 28, 2021 Processing time: 96 Days and 14.5 Hours
Core Tip
Core Tip: Achievement of hepatitis C virus (HCV) elimination using direct-acting antiviral drugs treatment by 2030 promoted by World Health Organization is hardly attainable especially amidst the coronavirus disease 2019 pandemic. The smaller goal of eliminating HCV from population segments for which tailored strategies of prevention and treatment can be easily implemented appears more realistic. Different specific populations and at-risk groups, as well as different settings including prisons and hospitals have been selected for micro-elimination campaigns. Dedicated micro-elimination strategies have also been designed at geographical level according to the countries income and HCV epidemiology. The success of micro-elimination depends on reliable epidemiological data and active involvement of all the different stakeholders.
